肿瘤检测技术

Search documents
华大基因:微小残留病(MRD)检测在美国市场目前较为火热
Zheng Quan Ri Bao Wang· 2025-08-26 10:16
Core Viewpoint - BGI Genomics (300676) has made significant advancements in the field of minimal residual disease (MRD) testing, particularly in the U.S. market, through collaboration with Natera since 2019 [1] Group 1: MRD Testing Market - The MRD testing market is currently thriving in the U.S., with companies like Natera achieving notable clinical and market progress [1] - BGI Genomics has integrated leading MRD testing technology into its offerings, establishing itself as one of the most comprehensive solutions in the domestic market [1] Group 2: Technical Approaches - There are different technical routes for MRD testing, with tumor-informed approaches providing stable applications, while tumor-agnostic routes cater to diverse needs [1] - The company is accelerating the development and application of tumor-agnostic technologies based on its proprietary technical system [1] Group 3: Non-invasive Screening Technology - BGI Genomics has made important progress in non-invasive tumor screening technology, which combines methylation features and fragmentomics without relying on tumor tissue samples [1] - This technology allows for high-precision, dynamic blood testing assessments, particularly suitable for health screenings and patients unable to access tumor tissue [1] - The company aims to integrate upstream tissue tracing functions with downstream clinical validation to enhance the synergy between MRD testing and screening applications [1]